Real-Life Adherence to Venom Immunotherapy and Adrenaline Autoinjector
International Archives of Allergy and Immunology · 2024
DOI: 10.1159/000535294 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2024. Verfasst von Louise Parke und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Insect Bites and Stings, Venom Hypersensitivity, Anaphylaxis, Mastocytosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Introduction
Venom immunotherapy (VIT) and adrenaline autoinjector (AAI) are important therapies in venom anaphylaxis. Adherence to VIT and AAI in patients with venom allergy has been evaluated in a few studies; however, solid data are lacking. This study aimed to evaluate VIT and AAI retrieval rates in patients with venom allergy with a special focus on adherence to treatment. Adherence was compared to subcutaneous immunotherapy (SCIT) with inhalant allergens.
Methods
This was a retrospective study among patients registered for allergen immunotherapy at the Allergy Center, Odense University Hospital, Denmark, from January 1, 2010, to December 31, 2014. Data on purchased immunotherapy and AAI were obtained from the Danish National Health Service Prescription Database. Multivariable logistic regression was used to analyze if allergen, age, sex, mastocytosis, and treatment site affected adherence.
Results
The 3-year adherence to VIT was 92.4% (244/264) compared to 87.4% (215/246) in SCIT with inhalant allergens, and the 5-year adherence to VIT was 84.1% (222/264) compared to 74.8% (184/246) in SCIT with inhalant allergens (p = 0.045). Females treated with VIT were more adherent than males (p = 0.45 [3-year], p = 0.008 [5-year]), whereas allergen, age, mastocytosis, or treatment site did not significantly affect adherence. Only 28.6% of patients (12/42) purchased an AAI after premature termination of VIT.
Conclusion
In this register-based study, we found that the 3- and 5-year adherences to VIT and SCIT with inhalant allergens are at the upper end of the spectrum hitherto reported. Patients’ 5-year adherence to VIT was higher than patients’ 5-year adherence to SCIT with inhalant allergens. If VIT was prematurely terminated, less than 1/3 would have purchased an AAI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.
- Institute of Clinical Research, Center for Clinical Epidemiology, Odense University Hospital, and Research Unit of Clinical Epidemiology, University of Southern Denmark, Odense, Denmark.
- Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.
Zitieren
APA
Parke, L., Fomsgaard Kjaer, H., Sivertsen Garvik, O., Halken, S., Broesby-Olsen, S., Bindslev-Jensen, C., & Mortz, C. G. (2024). Real-Life Adherence to Venom Immunotherapy and Adrenaline Autoinjector. International Archives of Allergy and Immunology. https://doi.org/10.1159/000535294
Vancouver
Parke L, Fomsgaard Kjaer H, Sivertsen Garvik O, Halken S, Broesby-Olsen S, Bindslev-Jensen C, et al. Real-Life Adherence to Venom Immunotherapy and Adrenaline Autoinjector. International Archives of Allergy and Immunology. 2024. doi:10.1159/000535294
BibTeX
@article{Parke2024,
author = {Parke, Louise and Fomsgaard Kjaer, Henrik and Sivertsen Garvik, Olav and Halken, Susanne and Broesby-Olsen, Sigurd and Bindslev-Jensen, Carsten and Mortz, Charlotte G},
title = {Real-Life Adherence to Venom Immunotherapy and Adrenaline Autoinjector},
journal = {International Archives of Allergy and Immunology},
year = {2024},
doi = {10.1159/000535294}
}
EUVIMED